– $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch –
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
Seeking Alpha / 2 hours from now 1 Views
Seeking Alpha / 2 hours from now 1 Views
– $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch –
Comments